STEROID-HORMONE LEVELS IN PATIENTS WITH ADVANCED BREAST-CANCER DURINGTHERAPY WITH DROLOXIFENE - A PILOT-STUDY

Citation
J. Dalski et M. Gorlich, STEROID-HORMONE LEVELS IN PATIENTS WITH ADVANCED BREAST-CANCER DURINGTHERAPY WITH DROLOXIFENE - A PILOT-STUDY, Tumori, 82(1), 1996, pp. 45-47
Citations number
14
Categorie Soggetti
Oncology
Journal title
TumoriACNP
ISSN journal
03008916
Volume
82
Issue
1
Year of publication
1996
Pages
45 - 47
Database
ISI
SICI code
0300-8916(1996)82:1<45:SLIPWA>2.0.ZU;2-E
Abstract
Antiestrogens, particularly tamoxifen, are effective in the treatment of pre- and postmenopausal women suffering from all stages of breast c ancer. Unfortunately, many patients become resistant to tamoxifen duri ng therapy, which allows the tumor to progress. Thus, a preclinical re cognition of tumor progression, i.e. by monitoring serum hormone level s, could be worthwhile. The serum levels of dehydroepiandrosterone sul fate and estradiol of postmenopausal women with advanced breast cancer treated by the new antiestrogen droloxifene were therefore checked. H owever, only non-significant changes in the hormone levels during drol oxifene therapy were observed, and no relation was found between hormo ne levels and the course of the disease, success or exhaustion of drol oxifene application, or development of tumor progression. Our data do not confirm earlier findings reported in the literature that measureme nt of hormones seems to be suitable for an early indication of tumor p rogression during an antiestrogen therapy before its clinical manifest ation.